Hyperthermic intraperitoneal chemotherapy after secondary cytoreduction in epithelial ovarian cancer: A single-center experience

2016 ◽  
Author(s):  
yeliz aykanat
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Single Center ◽  
Single Center Experience

Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis

2015 ◽  
Vol 23 (4) ◽  
pp. 1294-1301 ◽  
Author(s):  
Glauco Baiocchi ◽  
Fabio Oliveira Ferreira ◽  
Henrique Mantoan ◽  
Alexandre Andre Balieiro Anastacio da Costa ◽  
Carlos Chaves Faloppa ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Comparative Analysis ◽  
Epithelial Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Single Center

scholarly journals Intraperitoneal Chemotherapy for Epithelial Ovarian Cancer – Single Center Experience

2012 ◽  
Vol 3 (3) ◽  
pp. 262-266 ◽  
Author(s):  
Rajshekhar C. Jaka ◽  
S. P. Somashekhar ◽  
Shabber S. Zaveri ◽  
Zahoor Ahmed ◽  
K. R. Ashwin
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Single Center ◽  
Single Center Experience

scholarly journals Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Mette Schou Mikkelsen ◽  
Jan Blaakaer ◽  
Lone Kjeld Petersen ◽  
Luise Gram Schleiss ◽  
Lene Hjerrild Iversen
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Systemic Exposure ◽  
Hematological Toxicity ◽  
Pharmacokinetic Analysis ◽  
Pharmacokinetic Parameters ◽  
Severe Toxicity ◽  
Perfusion Time

AbstractObjectivesCarboplatin is frequently used in various doses for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of epithelial ovarian cancer (EOC) although its pharmacokinetics, including focus on the perfusion time, has not been evaluated when used in modern era cytoreductive surgery (CRS). The aim was to evaluate the pharmacokinetics and hematological toxicity of carboplatin used for HIPEC with a perfusion time of 90 min.MethodsFifteen patients with stage III–IV primary EOC received CRS and 90 min of HIPEC with carboplatin at dose 800 mg/m2. For the pharmacokinetic analysis, perfusate and blood samples were obtained during HIPEC and up to 48 h after HIPEC (blood only). Hematological toxicity within 30 days was graded according to Common Terminology Criteria for Adverse Events. Severe toxicity (grades 3–5) is reported.ResultsMean maximum concentration of carboplatin was 12 times higher in perfusate than plasma (mean CmaxPF=348 µg/mL (range: 279–595 µg/mL) versus mean CmaxPL=29 µg/mL (range: 21–39 µg/mL)). Mean terminal half-life of carboplatin in perfusate was 104 min (range: 63–190 min) and mean intraperitoneal-to-plasma area under the concentration-time curve (AUC) ratio was 12.3 (range: 7.4–17.2). Two patients (13%) had grade 3 neutropenia within 30 days. No grade 4–5 hematological toxicities were identified.ConclusionsCarboplatin has a favorable pharmacokinetic profile for 90 min HIPEC administration, and the hematological toxicity was acceptable at dose 800 mg/m2. Large interindividual differences were found in the pharmacokinetic parameters, making risk of systemic exposure difficult to predict.

Sign in / Sign up

Export Citation Format

Share Document